Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome

Inclusion Criteria: * （1）Patients with Nephrotic Syndrome： 1. Proteinuria greater than 3.5 g/24 hour 2. Serum albumin \<30 g/l 3. Clinical evidence of peripheral oedema 4. Hyperlipidemia 1) and 2) are necessary for diagnosis. * （2）18-75years old（include 75），gender is not limited； * （3）Voluntary signing informed consent。 Exclusion Criteria: * （1）Secondary nephrotic syndrome； * （2）Allergic to Tacrolimus or other unsuitable use of Tacrolimus； * （3）With other immunosuppressive agents such as cyclosporin A, cyclophosphamide, mycophenolate mofetil, leflunomide, tripterygium wilfordii (hormone is not restricted)； * （4）Severe liver dysfunction (transaminase \> 3 ULN, or bilirubin \> 3 ULN)； * （5）Severe renal insufficiency（eGFR\<30 ml/min/1.73m2） * （6）Joined other clinical trials within 1 month； * （7）Missing clinical data； * （8）Pregnancy, lactation or planning for pregnancy within 12 months； * （9）Researchers believe that patients who are not suitable for this clinical trial。